NextGen 2024: Refractory SJIA & MAS Session Part 7

NextGen 2024: Refractory SJIA & MAS Session Part 7

@SJIA_Foundation
@SJIA_Foundation
8 Followers
3 months ago 249
AI Summary
Bulleted
Text
Key Insights
  • Focus on next-generation therapies for Systemic Juvenile Idiopathic Arthritis (SJIA), Still's disease, and Macrophage Activation Syndrome (MAS).
  • Case studies of two pediatric patients: one with ATS presenting with Still's onset and MAS and another with JMA also presenting with Still's onset.
  • Treatment approaches including antiviral prophylaxis, antibacterial prophylaxis, IV MP pulses, and various medications like Anakinra, Tocilizumab, Tacrolimus, and Baricitinib are employed.
  • Patient monitoring involves tracking markers like WBC, ESR, CRP, ferritin, and LFT, with NGS panel for AID (Heterozygous DNASE2 c.995C>A VUS and PSMB8 c.-5C>T VUS) and PID performed.
#stillsdisease #sjiafoundation #macrophageactivation #sjia #curesjia
Refractory disease
(Still’s +/- MAS)
Juan Manuel Mosquera A. 
Pediatric Rheumatologist
Attendin…
1/4
• ATS, 11 yr, , 33 kg, latino origin
• Cholinergic urticaria and atopic dermatitis
• Typical Stil…
2/4
• JMA, , 13 yr, 45 kg, Philippine origin. Any relevant past history
• Typical Still disease onset …
3/4
Juanmanuel.mosquera@sjd.es
Enfermedades 
Autoinmunes y
Autoinflamatorias
XUEC en malalties 
au…
4/4

NextGen 2024: Refractory SJIA & MAS Session Part 7

  • 1. Refractory disease (Still’s +/- MAS) Juan Manuel Mosquera A. Pediatric Rheumatologist Attending physician at Pediatric Rheumatology section in Sant Joan de Déu Children’s Hospital
  • 2. • ATS, 11 yr, , 33 kg, latino origin • Cholinergic urticaria and atopic dermatitis • Typical Still onset – MAS (Fever, arthralgia, sore throat, rash) • ↑WBC, ESR, CRP, ferritin, LFT, S100A8/A9, IL18 and triglycerids, ↓ PLT, fibrinogen. HLA-DRB1*15 • NGS panel for AID (Heterozygous DNASE2 c.995C>A VUS and PSMB8 c.-5C>T VUS) and PID performed • HRCT negative • Antiviral and antibacterial prophylaxis CS + ANK + CsA + IVIG Emapalumab (+CS + ANK + CsA) CS + ANK + CsA TCZ + CsA (+CS) TCZ (+CS) TK + IVIG (+TCZ + CS) SARS-CoV2 CMV reactivation Adenovirus SARS-CoV2 Adenovirus CMV reactivation Rhino/Enterovirus Rhino/Enterovirus Rhino/Enterovirus
  • 3. • JMA, , 13 yr, 45 kg, Philippine origin. Any relevant past history • Typical Still disease onset (fever, sore throat, myalgia, rash, serositis, w/o arthritis) • ↑WBC, ESR, CRP, ferritin, LFT, S100A8/A9, IL18 and 🡪 PLT, fibrinogen, triglycerids. HLA-DRB1*15 • HRCT negative • DRESS like reaction (26/05/24) 🡪 Rash and ↑LFT IV MP pulses + oral CS Anakinra 2,2 mg/kg (+ CS) Tocilizumab 8 mg/kg (+ CS) Tacrolimus 0,1 mg/kg (+ CS) Baricitinib 4 mg/d (+ TK + CS)
  • 4. Juanmanuel.mosquera@sjd.es Enfermedades Autoinmunes y Autoinflamatorias XUEC en malalties autoimmunes sistèmiques I autoinflamatòries


  • Previous
  • Next
  • f Fullscreen
  • esc Exit Fullscreen
@SJIA_Foundation

Share

NextGen 2024: Refractory SJIA & MAS Session Part 7

Embed code

Report Inappropriate Content on Jaunt

Choose the reason you are reporting: NextGen 2024: Refractory SJIA & MAS Session Part 7 as inappropriate to Jaunt's content team.


Swipe LEFT
to view Related

Scroll DOWN
to read doc

Cookies to automatically collect, record, and share information about your interactions with our site for analytics purposes.
Cookies used to enable advertising on our site.

Login

OR

Forgot password?

Don't have an account? Sign Up